Biocon shares rise 2% after USFDA has concluded inspection with 5 observations

Biocon shares rose 2% to RS 364 on Friday 5 September, after the announcement of the company that the US Food and Drug Administration (FDA) has completed a routine good manufacturing practice (CGMP) -Specture (CGMP) on Biocon Biocon -Campance Facility in the Biocon -Campance Facility Observations.

The Inspectorate, carried out between August 26 and September 3, 2025, included various operational areas, including production units of medicines, analytical quality control laboratories, microbiologiebs and warehouses.

At the end of the inspection, the American FDA has issued a form 483 with five procedural observations.

According to the company, these observations are not related to data integrity, systemic non-compliance or quality overview. They are rather procedural in nature and do not increase red flags about the quality systems or compliance methods of the company.

Biocon Biologics confirmed that it will submit a corrective and preventive action (CAPA) plan within the certain timeline and has faith in the ability to tackle all observations quickly.

It is important that the company stated that it has no influence on an impact on the range of its commercial products, relating to concerns about product disruptions or escalations for regulations. “Biocon Biologics zal een uitgebreid corrigerende en preventieve actie (CAPA) -plan (CAPA) -plan in het aanbod van zijn commerciële producten in het leveren van zijn commerciële producten, in het aanbod van zijn commerciële producten, in het aanbod van zijn commerciële producten, zullen het bedrijf niet in het aanbod van zijn commerciële producten in het aanbod van het aanbod van het bedrijf, het bedrijf in het aanbod van zijn commerciële producten, in het aanbod van zijn commerciële producten, zullen het bedrijf niet in het aanbod van zijn Commercial products, “his dedication repeated to maintain the highest standards of quality and compliance and insured stakeholders of continuous cooperation with global regulatory authorities.

Read also: You make 12-15% CAGR but do not invest for 5-6 months Horizons: ROODEO Agrawal

(Disclaimer: recommendations, suggestions, views and opinions of the experts are their own. These do not represent the views of economic times)

An evening in Lal Qila, 27 September 2025 – reserved for Times Black Icici Bank -credit card holders. Access to monumental experiences at Timesblack.com